Literature DB >> 15471162

Closure of defects of the atrial septum in adults using the Amplatzer device: 100 consecutive patients in a single center.

I F Purcell1, S J Brecker, D E Ward.   

Abstract

BACKGROUND: Transcatheter device closure of atrial septal defects (ASD) is an alternative to surgery, but experience is limited in adults, especially in those with large (> 26 mm) defects. HYPOTHESIS: We investigated the safety, efficacy, and learning curve for closure of ASD and patent foramen ovale (PFO) using the Amplatzer device.
METHODS: In all, 101 procedures were carried out in 100 consecutive adult patients in a single cardiac center between July 1998 and August 2002.
RESULTS: Preprocedure diagnosis was ASD and PFO in 50 patients each. A device was deployed in 94 of 101 attempts (93%) in 94 of 100 patients (94%). Atrial septal defect device sizes were 10-38 mm, median 24 mm, and 40% were > 26 mm. Major complications occurred in 2 of 100 patients (2%). One ASD device displaced requiring surgery within 24 h and one patient with PFO experienced pericardial tamponade; there were no deaths. Local vascular complications occurred in 4 of 100 (4%) and late complications in 4 of 100 (4%) patients. Patent foramen ovale closure was quicker (p<0.001), required less radiation (p=0.04), and was associated with fewer local vascular complications than ASD closure (p=0.04). Deployment of ASD devices > 26 mm was not associated with increased complications, length of procedure, or radiation compared with devices < or = 26 mm (all p>0.05). Complications in the first 35 patients were more frequent than in subsequent patients: 7 of 35 (20%) versus 3 of 65 (4.6%) (p=0.04); procedure and fluoroscopy times (both p<0.001) and radiation doses (p=0.001) were also higher.
CONCLUSION: The Amplatzer device is an effective method for transcatheter closure of interatrial defects in adults, including large ASDs up to 38 mm. Major complications are uncommon. A learning curve of approximately 35 cases was suggested by the decline of complications, procedure times, and radiation exposure.

Entities:  

Mesh:

Year:  2004        PMID: 15471162      PMCID: PMC6654089          DOI: 10.1002/clc.4960270907

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  28 in total

1.  Transcatheter closure of atrial septal defects without fluoroscopy: feasibility of a new method.

Authors:  P Ewert; F Berger; I Daehnert; J van Wees; M Gittermann; H Abdul-Khaliq; P E Lange
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

2.  Transesophageal echocardiographic results of catheter closure of atrial septal defect in children and adults using the Amplatzer device.

Authors:  Z M Hijazi; Q Cao; H T Patel; J Rhodes; K M Hanlon
Journal:  Am J Cardiol       Date:  2000-06-01       Impact factor: 2.778

3.  Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience.

Authors:  K C Chan; M J Godman; K Walsh; N Wilson; A Redington; J L Gibbs
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

4.  Comparison of results and complications of surgical and Amplatzer device closure of atrial septal defects.

Authors:  F Berger; M Vogel; V Alexi-Meskishvili; P E Lange
Journal:  J Thorac Cardiovasc Surg       Date:  1999-10       Impact factor: 5.209

5.  Transcatheter closure as standard treatment for most interatrial defects: experience in 200 patients treated with the Amplatzer Septal Occluder.

Authors:  F Berger; P Ewert; P G Björnstad; I Dähnert; G Krings; I Brilla-Austenat; M Vogel; P E Lange
Journal:  Cardiol Young       Date:  1999-09       Impact factor: 1.093

6.  Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder.

Authors:  G Fischer; H H Kramer; J Stieh; P Harding; O Jung
Journal:  Eur Heart J       Date:  1999-04       Impact factor: 29.983

7.  Transcatheter closure of atrial septal defects in adults with the Amplatzer septal occluder.

Authors:  R Dhillon; B Thanopoulos; G Tsaousis; F Triposkiadis; M Kyriakidis; A Redington
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

8.  Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.

Authors:  J Hung; M J Landzberg; K J Jenkins; M E King; J E Lock; I F Palacios; P Lang
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

9.  Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events.

Authors:  S Windecker; A Wahl; T Chatterjee; A Garachemani; F R Eberli; C Seiler; B Meier
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

10.  Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers.

Authors:  K P Walsh; P T Wilmshurst; W L Morrison
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

View more
  1 in total

1.  Acute renal failure and multiple sites of ischaemia: what is the unifying diagnosis?

Authors:  Kirsty Le Doaré; Seyed Ameli-Renani; Debasish Banerjee; Stephen J D Brecker; John B Eastwood
Journal:  NDT Plus       Date:  2008-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.